Zynerba Pharmaceuticals Enters Into Equity Purchase AgreementĀ for Up to $20 Million with Lincoln Park Capital
DEVON, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...